12:00 AM
Jul 21, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Status

TKM-Ebola: Phase I hold

Tekmira said FDA placed a full clinical hold on a single-blind, placebo-controlled, U.S. Phase I trial of IV TKM-Ebola after the company completed the single ascending-dose portion of the trial, which evaluated doses of 0.075-0.3 mg/kg in 19 healthy volunteers. According to the company, FDA requested additional data related to the mechanism of cytokine release that was observed in a single volunteer at higher doses and a protocol modification...

Read the full 321 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >